Table 4 Summary of results for... | American Society of Hematology

Table 4

Summary of results for cyclophosphamide therapy in patients with LGL leukemia

No. of patients	Duration of treatment, mo	Time to response, wk	ORR, %	CHR, %	Comments	Reference (year)
9	6-12	—	65†	—	All patients had PRCA	71 (2001)
16	12	—	69‡	—	13 as second-line 80% responses unmaintained	59 (1994)
4*	1.3-10	4	33	33	1 CHR > 7 years	65 (2006)
8	24 (10-124)	1	75	—	All patients had PRCA	72 (2008)
16	—	—	44	—	11 of 16 as a second-line	13 (2009)
32	6-12	—	66	—	First-line: n = 4, second-line n = 12, third-line: n = 16, 6 CR 12-48 mos after therapy cessation	12 (2010)
Total (n = 85)			52/85 (61%)

No. of patients	Duration of treatment, mo	Time to response, wk	ORR, %	CHR, %	Comments	Reference (year)
9	6-12	—	65†	—	All patients had PRCA	71 (2001)
16	12	—	69‡	—	13 as second-line 80% responses unmaintained	59 (1994)
4*	1.3-10	4	33	33	1 CHR > 7 years	65 (2006)
8	24 (10-124)	1	75	—	All patients had PRCA	72 (2008)
16	—	—	44	—	11 of 16 as a second-line	13 (2009)
32	6-12	—	66	—	First-line: n = 4, second-line n = 12, third-line: n = 16, 6 CR 12-48 mos after therapy cessation	12 (2010)
Total (n = 85)			52/85 (61%)

ORR indicates overall response rate; CHR, complete hematologic response; —, not applicable; PRCA, pure red cell aplasia; and CR, complete response.

A total of 50-100 mg/day or 250-500 mg intravenously.

Four of 5 patients responded as front-line therapy.

A total of 80% as second-line therapy.